FluxMPS™ Iscove's Modified Dulbecco's Medium (IMDM) High Glucose w/o Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ Iscove's Modified Dulbecco's Medium (IMDM) High Glucose w/o Sodium Bicarbonate, Phenol Red: 1X Liquid

An MPS-grade, high-glucose Iscove's Modified Dulbecco's Medium re-engineered for microphysiological systems and microfluidic channels. Quadruple-stage ultra-filtration (0.1 µm ×2 + 0.04 µm ×2) delivers media approximately 5× cleaner than conventional 0.22 µm formulations, with an endotoxin specification below 0.05 EU/mL and Ultrapure Type 1 water.

• Nano-filtered, microchannel-safe formulation engineered for microphysiological systems (MPS) and organ-on-a-chip (OoC) platforms
• FluxMPS™ Quadruple-stage filtration architecture (0.1 µm ×2 + 0.04 µm ×2) for ultra-low particulate, sub-mycoplasma polishing
• Endotoxin specification < 0.05 EU/mL by USP <85> BET, supporting low-background live-cell imaging and biosensing
• Iscove's Modified Dulbecco's Medium (high-glucose); without sodium bicarbonate, phenol red-free
• Formulated with Ultrapure Type 1 water (18.2 MΩ·cm) for ultra-clean microfluidic perfusion
• ISO Class 5 (Class 100) aseptic fill & finish under an ISO 13485:2016 quality management system
• pH, glucose concentration, salts, HEPES, and nutrient composition available on request

Engineered where standard 0.22 µm media fails

Conventional 0.22 µm-filtered media can carry subvisible particulates and mycoplasma-scale contaminants (the smallest mycoplasma are ~0.2 µm) that accumulate in microfluidic channels, corrupt biosensor signals, and shorten perfusion runs. FluxMPS™ IMDM, High Glucose w/o Bicarbonate, Phenol Red is re-engineered for these microphysiological systems.^[1,2]

Quadruple-stage filtration system

The FluxMPS™ purity architecture is built around a four-stage membrane train (0.1 µm ×2 + 0.04 µm ×2), positioning DCP-IMDM-BR1X as a ready-to-use, ultra-clean medium for microfluidic and organ-on-a-chip work at a purity level conventional 0.22 µm media cannot reach.^[2,3]

1. 1

   0.1 µmPre-filtration I

   Large particulate and aggregate removal that extends downstream filter life and protects the polishing stages.

2. 2

   0.04 µmPre-filtration II

   Fine-particulate reduction with bacteria and mycoplasma-scale retention ahead of sterile filtration.

3. 3

   0.1 µmSterile-filtration I

   Second-pass redundancy for robust, validated sterility assurance.

4. 4

   0.04 µmSterile-filtration II — Final Polish

   Ultimate ultra-low-particulate polish, filled under an ISO Class 5 (Class 100) aseptic environment.

Built for microphysiological & organ-on-a-chip research

IMDM, High Glucose w/o Bicarbonate, Phenol Red supports rapidly proliferating, high-density cultures — from erythroid progenitors, macrophages, and B/T lymphocytes to hybridomas — and is well suited to perfused MPS, metabolic, and imaging applications.^[1,4]

Automated Bioreactors & Robotics

For automated bioreactors and robotic perfusion platforms, an optional 10 nm (0.01 µm) ultra-filtered grade is available to push particulate exclusion beyond the standard 0.04 µm polish.

• Total particulate exclusion for narrow microchannels and high-resolution optics
• Valve & sensor protection across long unattended runs
• Extended perfusion stability for multi-week organ-on-a-chip experiments

Inquiry Required: the optional 0.01 µm (10 nm) grade is made to order — contact support@diagnocine.com to request it.

Technical specifications

Representative specifications for DCP-IMDM-BR1X. Values are confirmed per lot on the Certificate of Analysis.

Full composition (mg/L)

Complete defined formulation of DCP-IMDM-BR1X, released on a per-lot basis. All 39 components and their mg/L values are reproduced from the validated formulation.

Manufacturing & compliance

All final packaging, quality assurance, and testing for DCP-IMDM-BR1X are completed at the Diagnocine R&D and Quality Testing Center; customization and assembly are performed at Diagnocine Precision, Totowa, New Jersey, USA.

How DCP-IMDM-BR1X compares

DCP-IMDM-BR1X versus conventional 0.22 µm-filtered IMDM and a standard 0.22 µm-filtered DMEM-class alternative.

Frequently asked questions

Common questions about DCP-IMDM-BR1X for microphysiological and standard cell-culture workflows.

Supporting literature

Peer-reviewed literature supporting the use of enriched, ultra-filtered media in microphysiological and metabolic research.

1. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–772.doi:10.1038/nbt.2989
2. Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development. Cell Stem Cell. 2018;22(3):310–324.doi:10.1016/j.stem.2018.02.011
3. Halldorsson S, et al. Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices. Biosens Bioelectron. 2015;63:218–231.doi:10.1016/j.bios.2014.07.029
4. Iscove NN, Melchers F. Complete replacement of serum by albumin, transferrin, and soybean lipid in cultures of lipopolysaccharide-reactive B lymphocytes. J Exp Med. 1978;147(3):923–933.doi:10.1084/jem.147.3.923
5. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.doi:10.1126/science.1160809
6. Nikolaev M, et al. Homeostatic mini-intestines through scaffold-guided organoid morphogenesis. Nature. 2020;585(7826):574–578.doi:10.1038/s41586-020-2724-8
7. Drexler HG, Uphoff CC. Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology. 2002;39(2):75–90.doi:10.1023/A:1022913015916
8. Booth R, Kim H. Characterization of a microfluidic in vitro model of the blood-brain barrier. Lab Chip. 2012;12(10):1784–1792.doi:10.1039/c2lc40094d
9. Whitesides GM. The origins and the future of microfluidics. Nature. 2006;442(7101):368–373.doi:10.1038/nature05058
10. Low LA, Mummery C, Berridge BR, et al. Organs-on-chips: into the next decade. Nat Rev Drug Discov. 2021;20(5):345–361.doi:10.1038/s41573-020-0079-3